@article{1f82d45f4d374d5ba45f687a271c2387,
title = "Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease",
abstract = "Introduction: Cognitive dysfunction is common in Parkinson's disease (PD) and associated with reduced functional abilities and increased dependence. To date, however, little is known about the relationship between performance of instrumental activities of daily living (IADLs) and cognitive stages in PD, and there are conflicting reports as to whether declines in specific cognitive domains predict IADL impairment. Methods: Participants with PD were drawn from the Pacific Udall Center and included in the study if both participant and study partner IADL ratings and cognitive tests were completed (n = 192). Logistic regression analyses were performed to determine whether participant and/or study partner rating predicted mild cognitive impairment or dementia. Correlations are reported for the relationship between participant/study partner IADL reports as well as for specific cognitive tests. Results: Although both participant and study partner ratings of IADL performance were associated with a diagnosis of PD with dementia, only participant self-rating of functional ability was significantly associated with a diagnosis of PD with mild cognitive impairment. Functional ability correlated most strongly with measures of processing speed, auditory working memory, and immediate verbal recall for both the participant and study partner ratings. Conclusion: For participants with PD in the early stages of cognitive decline, self-rating may be more sensitive to the impact of cognitive changes on IADL function than ratings made by a knowledgeable study partner. Changes in executive function, processing speed, and learning may indicate a higher likelihood of IADL impairment. Careful assessment of cognition and IADL performance is recommended to permit individualized interventions prior to significant disability.",
keywords = "Activities of daily living, Parkinson's disease, cognition, dementia, mild cognitive impairment, study partner",
author = "Brenna Cholerton and Poston, {Kathleen L.} and Lu Tian and Quinn, {Joseph F.} and Chung, {Kathryn A.} and Hiller, {Amie L.} and Hu, {Shu Ching} and Krista Specketer and Montine, {Thomas J.} and Edwards, {Karen L.} and Zabetian, {Cyrus P.}",
note = "Funding Information: Dr. Cholerton is supported by grants from the National Institutes of Health (NIH). Dr. Poston reports honoraria from invited scientific presentations to universities and professional societies not exceeding $5,000 per year, is reimbursed by AstraZeneca and Sangamo BioSciences, Inc. for the conduct of clinical trials, receives consulting fees from Allergan and Curasen, and is funded by grants from the NIH and Michael J. Fox Foundation. Dr. Tian is supported by grants from the NIH. Dr. Quinn is reimbursed by Prothena and Roche for the conduct of clinical trials and by vTv Pharmaceuticals for Data Safety Monitoring Board service. Dr. Quinn is also supported by grants from the NIH and Department of Veterans Affairs. Dr. Chung is funded by a Veterans Affairs Merit Grant. Dr. Hiller is reimbursed by Theravance Inc. for conducting clinical trials and supported by grants from NIH. Ms. Specketer is supported by grants from the NIH. Dr. Hu is funded by grants from the NIH and Michael J. Fox Foundation. Dr. Montine reports honoraria from invited scientific presentations to universities and professional societies not exceeding $5,000 per year and is funded by grants from the NIH and the Farmer Family Foundation, and a gift from Regina and John Scully. Dr. Edwards is funded by grants from the NIH. Dr. Zabetian was supported by grants from the American Parkinson Disease Association, Department of Veteran Affairs, and NIH, and a gift from the Dolsen Foundation. Funding Information: This work was supported by the Department of Veterans Affairs and National Institutes of Neurological Disorders and Stroke grant P50 NS062684. The funding sources did not provide scientific input for the study. The authors declare that there are no conflicts of interest relevant to this work. Publisher Copyright: {\textcopyright} 2019 International Parkinson and Movement Disorder Society",
year = "2020",
month = jan,
day = "1",
doi = "10.1002/mdc3.12870",
language = "English (US)",
volume = "7",
pages = "61--69",
journal = "Movement Disorders Clinical Practice",
issn = "2330-1619",
publisher = "John Wiley and Sons Ltd",
number = "1",
}